Browse PXDN

Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix Note=Enriched in the peritubular space of fibrotic kidneys.
Domain PF03098 Animal haem peroxidase
PF07679 Immunoglobulin I-set domain
PF13855 Leucine rich repeat
PF00093 von Willebrand factor type C domain
Function

Displays low peroxidase activity and is likely to participate in H(2)O(2) metabolism and peroxidative reactions in the cardiovascular system. Plays a role in extracellular matrix formation.

> Gene Ontology
 
Biological Process GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001960 negative regulation of cytokine-mediated signaling pathway
GO:0006979 response to oxidative stress
GO:0009636 response to toxic substance
GO:0030198 extracellular matrix organization
GO:0042743 hydrogen peroxide metabolic process
GO:0042744 hydrogen peroxide catabolic process
GO:0043062 extracellular structure organization
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0072593 reactive oxygen species metabolic process
GO:0098754 detoxification
GO:0098869 cellular oxidant detoxification
GO:1990748 cellular detoxification
Molecular Function GO:0004601 peroxidase activity
GO:0005126 cytokine receptor binding
GO:0005152 interleukin-1 receptor antagonist activity
GO:0005201 extracellular matrix structural constituent
GO:0016209 antioxidant activity
GO:0016684 oxidoreductase activity, acting on peroxide as acceptor
GO:0019838 growth factor binding
GO:0019955 cytokine binding
GO:0019966 interleukin-1 binding
GO:0020037 heme binding
GO:0030545 receptor regulator activity
GO:0030547 receptor inhibitor activity
GO:0046906 tetrapyrrole binding
GO:0048019 receptor antagonist activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PXDN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PXDN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PXDN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.6460.00494
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.5020.403
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.740.158
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0840.84
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1690.943
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0310.992
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6160.311
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4150.799
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7790.678
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2040.456
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.020.372
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3770.0322
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PXDN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PXDN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PXDN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PXDN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PXDN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PXDN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PXDN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPXDN
Nameperoxidasin
Aliases KIAA0230; MG50; D2S448; D2S448E; peroxidasin homolog (Drosophila); COPOA; VPO; melanoma-associated antigen M ......
Chromosomal Location2p25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PXDN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.